Skip to main content

PLATAFORMAS NANOPLASMONICAS POINT-OF-CARE COMO SISTEMA INNOVADOR DE DIAGNOSTICO Y SEGUIMIENTO DE TERAPIAS

BES-2017-080527

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Formación
Call Contratos Predoctorales
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIÓ INSTITUT CATALÀ DE NANOCIÈNCIA I NANOTECNOLOGIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

One-step and real-time detection of microRNA-21 in human samples for lung cancer biosensing diagnosis

  • Calvo-Lozano, Olalla
  • García-Aparicio, Pablo
  • Raduly, Lajos-Zsolt
  • Estévez, M. Carmen
  • Berindan-Neagoe, Ioana
  • Ferracin, Manuela
  • Lechuga, Laura M.
The rapid diagnosis of cancer, especially in its early stages, is crucial for on-time medical treatment and for increasing the patient survival rate. Lung cancer shows the highest mortality rate and the lowest 5-year survival rate due to the late diagnosis in advanced cancer stages. Providing rapid and reliable diagnostic tools is a top priority to address the problem of a delayed cancer diagnosis. We introduce a nanophotonic biosensor for the direct and real-time detection in human plasma of the microRNA-21-5p biomarker related to lung cancer. The biosensor employs a silicon photonic bimodal interferometric waveguide that provides a highly sensitive detection in a label-free format. We demonstrate a very competitive detectability for direct microRNA-21-5p biomarker assays in human plasma samples (estimated LOD: 25 pM). The diagnostic capability of our biosensor was validated by analyzing 40 clinical samples from healthy individuals and lung cancer patients, previously analyzed by reverse-transcription quantitative polymerase chain reaction (qRT-PCR). We could successfully identify and quantify the levels of microRNA in a one-step assay, without the need for DNA extraction or amplification steps. The study confirmed the significance of implementing this biosensor technique compared to the benchmarking molecular analysis and showed excellent agreement with previous results employing the traditional qRT-PCR. This work opens new possibilities for the true implementation of point-of-care biosensors that enable fast, simple, and efficient early diagnosis of cancer diseases., The ICN2 acknowledges the financial support from the Spanish Research Agency (AEI), Ministry of Science, Innovation, and Universities through the PREDICT (TEC2016-78515-R) and EROICA PID2019-105132RB-I00) projects. ICN2 is funded by the CERCA Program/Generalitat de Catalunya and supported by the Severo Ochoa Centres of Excellence program funded by the Spanish Research Agency (AEI, grant no. SEV-2017-0706). O.C-L. acknowledges the economic support from the Spanish Ministry of Science and Innovation and the Spanish Research Agency and the European Social Fund (ESF) (ref. BES-2017-080527) linked to the PREDICT project. Research Center for Functional Genomics, Biomedicine and Translational Medicine acknowledges “Clinical and economic impact of personalized targeted anti-microRNA therapies in reconverting lung cancer chemoresistance”, CANTEMIR, no. POC-P_37_796/2016. This work was supported by the FLAG-ERA grant LEGOCHIP, funded by the Italian National Research Council and the Spanish National Research Agency (PCI2019-111890-2)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Advanced Evanescent-Wave Optical Biosensors for the Detection of Nucleic Acids, An Analytic Perspective

  • Huertas, César S.|||0000-0002-3100-4034
  • Calvo Lozano, Olalla|||0000-0001-5486-2237
  • Mitchell, Arnan
  • Lechuga, Laura M.|||0000-0001-5187-5358
Evanescent-wave optical biosensors have become an attractive alternative for the screening of nucleic acids in the clinical context. They possess highly sensitive transducers able to perform detection of a wide range of nucleic acid-based biomarkers without the need of any label or marker. These optical biosensor platforms are very versatile, allowing the incorporation of an almost limitless range of biorecognition probes precisely and robustly adhered to the sensor surface by covalent surface chemistry approaches. In addition, their application can be further enhanced by their combination with different processes, thanks to their integration with complex and automated microfluidic systems, facilitating the development of multiplexed and user-friendly platforms. The objective of this work is to provide a comprehensive synopsis of cutting-edge analytical strategies based on these label-free optical biosensors able to deal with the drawbacks related to DNA and RNA detection, from single point mutations assays and epigenetic alterations, to bacterial infections. Several plasmonic and silicon photonic-based biosensors are described together with their most recent applications in this area. We also identify and analyse the main challenges faced when attempting to harness this technology and how several innovative approaches introduced in the last years manage those issues, including the use of new biorecognition probes, surface functionalization approaches, signal amplification and enhancement strategies, as well as, sophisticated microfluidic solutions.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Fast and accurate pneumocystis pneumonia diagnosis in human samples using a label-free plasmonic biosensor

  • Calvo Lozano, Olalla|||0000-0001-5486-2237
  • Aviñó, Ana|||0000-0003-3047-738X
  • Friaza, Vicente|||0000-0002-2900-4334
  • Medina Escuela, Alfonso
  • Huertas, César S.|||0000-0002-3100-4034
  • Calderón, Enrique J.|||0000-0002-3166-5086
  • Eritja, Ramon|||0000-0001-5383-9334
  • Lechuga, Laura M.|||0000-0001-5187-5358
Pneumocystis jirovecii is a fungus responsible for human Pneumocystis pneumonia, one of the most severe infections encountered in immunodepressed individuals. The diagnosis of Pneumocystis pneumonia continues to be challenging due to the absence of specific symptoms in infected patients. Moreover, the standard diagnostic method employed for its diagnosis involves mainly PCR-based techniques, which besides being highly specific and sensitive, require specialized personnel and equipment and are time-consuming. Our aim is to demonstrate an optical biosensor methodology based on surface plasmon resonance to perform such diagnostics in an efficient and decentralized scheme. The biosensor methodology employs poly-purine reverse-Hoogsteen hairpin probes for the detection of the mitochondrial large subunit ribosomal RNA (mtLSU rRNA) gene, related to P. jirovecii detection. The biosensor device performs a real-time and label-free identification of the mtLSU rRNA gene with excellent selectivity and reproducibility, achieving limits of detection of around 2.11 nM. A preliminary evaluation of clinical samples showed rapid, label-free and specific identification of P. jirovecii in human lung fluids such as bronchoalveolar lavages or nasopharyngeal aspirates. These results offer a door for the future deployment of a sensitive diagnostic tool for fast, direct and selective detection of Pneumocystis pneumonia disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology, Implementation and Clinical Validation

  • Calvo Lozano, Olalla|||0000-0001-5486-2237
  • Sierra, Miquel
  • Soler Aznar, Maria|||0000-0001-7232-2277
  • Estévez, M. Carmen|||0000-0003-3694-7186
  • Chiscano-Camón, Luis|||0000-0003-0037-0610
  • Ruiz-Sanmartin, Adolfo
  • Ruiz-Rodriguez, Juan Carlos|||0000-0001-7392-8617
  • Ferrer, Ricard|||0000-0002-4859-4747
  • González-López, Juanjo|||0000-0003-2419-5909
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Fernandez-Naval, Candela|||0000-0002-5584-3537
  • Bueno, Leticia
  • López-Aladid, Ruben
  • Torres, Antoni|||0000-0002-8643-2167
  • Fernández Barat, Laia|||0000-0001-7528-9636
  • Attoumani, Sarah
  • Charrel, Rémi
  • Coutard, Bruno
  • Lechuga, Laura M.|||0000-0001-5187-5358
Serological tests are essential for the control and management of COVID-19 pandemic (diagnostics and surveillance, and epidemiological and immunity studies). We introduce a direct serological biosensor assay employing proprietary technology based on plasmonics, which offers rapid (<15 min) identification and quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in clinical samples, without signal amplification. The portable plasmonic device employs a custom-designed multiantigen (RBD peptide and N protein) sensor biochip and reaches detection limits in the low ng mL -1 range employing polyclonal antibodies. It has also been implemented employing the WHO-approved anti-SARS-CoV-2 immunoglobulin standard. A clinical validation with COVID-19 positive and negative samples (n = 120) demonstrates its excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor as an accurate and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the disease management and for the evaluation of immunological status during vaccination or treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

One-step and real-time detection of microRNA-21 in human samples for lung cancer biosensing diagnosis

  • Calvo Lozano, Olalla|||0000-0001-5486-2237
  • García Aparicio, Pablo|||0000-0001-9908-9639
  • Raduly, Lajos-Zsolt|||0000-0002-3926-5423
  • Estévez, M. Carmen|||0000-0003-3694-7186
  • Berindan Neagoe, Ioana|||0000-0001-5828-1325
  • Ferracin, Manuela|||0000-0002-1595-6887
  • Lechuga, Laura M|||0000-0001-5187-5358
The rapid diagnosis of cancer, especially in its early stages, is crucial for on-time medical treatment and for increasing the patient survival rate. Lung cancer shows the highest mortality rate and the lowest 5-year survival rate due to the late diagnosis in advanced cancer stages. Providing rapid and reliable diagnostic tools is a top priority to address the problem of a delayed cancer diagnosis. We introduce a nanophotonic biosensor for the direct and real-time detection in human plasma of the microRNA-21-5p biomarker related to lung cancer. The biosensor employs a silicon photonic bimodal interferometric waveguide that provides a highly sensitive detection in a label-free format. We demonstrate a very competitive detectability for direct microRNA-21-5p biomarker assays in human plasma samples (estimated LOD: 25 pM). The diagnostic capability of our biosensor was validated by analyzing 40 clinical samples from healthy individuals and lung cancer patients, previously analyzed by reverse-transcription quantitative polymerase chain reaction (qRT-PCR). We could successfully identify and quantify the levels of microRNA in a one-step assay, without the need for DNA extraction or amplification steps. The study confirmed the significance of implementing this biosensor technique compared to the benchmarking molecular analysis and showed excellent agreement with previous results employing the traditional qRT-PCR. This work opens new possibilities for the true implementation of point-of-care biosensors that enable fast, simple, and efficient early diagnosis of cancer diseases.